000007800312/312021Q3false00000780032021-01-012021-10-030000078003us-gaap:CommonStockMember2021-01-012021-10-030000078003pfe:NotesDue20220.250Member2021-01-012021-10-030000078003pfe:NotesDue20271.000Member2021-01-012021-10-03xbrli:shares00000780032021-11-08iso4217:USD00000780032021-07-052021-10-0300000780032020-06-292020-09-2700000780032020-01-012020-09-27iso4217:USDxbrli:shares00000780032021-10-0300000780032020-12-310000078003us-gaap:PreferredStockMember2021-07-040000078003us-gaap:CommonStockMember2021-07-040000078003us-gaap:AdditionalPaidInCapitalMember2021-07-040000078003us-gaap:TreasuryStockMember2021-07-040000078003us-gaap:RetainedEarningsMember2021-07-040000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-040000078003us-gaap:ParentMember2021-07-040000078003us-gaap:NoncontrollingInterestMember2021-07-0400000780032021-07-040000078003us-gaap:RetainedEarningsMember2021-07-052021-10-030000078003us-gaap:ParentMember2021-07-052021-10-030000078003us-gaap:NoncontrollingInterestMember2021-07-052021-10-030000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-052021-10-030000078003us-gaap:CommonStockMember2021-07-052021-10-030000078003us-gaap:AdditionalPaidInCapitalMember2021-07-052021-10-030000078003us-gaap:TreasuryStockMember2021-07-052021-10-030000078003us-gaap:PreferredStockMember2021-10-030000078003us-gaap:CommonStockMember2021-10-030000078003us-gaap:AdditionalPaidInCapitalMember2021-10-030000078003us-gaap:TreasuryStockMember2021-10-030000078003us-gaap:RetainedEarningsMember2021-10-030000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-10-030000078003us-gaap:ParentMember2021-10-030000078003us-gaap:NoncontrollingInterestMember2021-10-030000078003us-gaap:PreferredStockMember2020-06-280000078003us-gaap:CommonStockMember2020-06-280000078003us-gaap:AdditionalPaidInCapitalMember2020-06-280000078003us-gaap:TreasuryStockMember2020-06-280000078003us-gaap:RetainedEarningsMember2020-06-280000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-280000078003us-gaap:ParentMember2020-06-280000078003us-gaap:NoncontrollingInterestMember2020-06-2800000780032020-06-280000078003us-gaap:RetainedEarningsMember2020-06-292020-09-270000078003us-gaap:ParentMember2020-06-292020-09-270000078003us-gaap:NoncontrollingInterestMember2020-06-292020-09-270000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-292020-09-270000078003us-gaap:CommonStockMember2020-06-292020-09-270000078003us-gaap:AdditionalPaidInCapitalMember2020-06-292020-09-270000078003us-gaap:TreasuryStockMember2020-06-292020-09-270000078003us-gaap:PreferredStockMember2020-09-270000078003us-gaap:CommonStockMember2020-09-270000078003us-gaap:AdditionalPaidInCapitalMember2020-09-270000078003us-gaap:TreasuryStockMember2020-09-270000078003us-gaap:RetainedEarningsMember2020-09-270000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-270000078003us-gaap:ParentMember2020-09-270000078003us-gaap:NoncontrollingInterestMember2020-09-2700000780032020-09-270000078003us-gaap:PreferredStockMember2020-12-310000078003us-gaap:CommonStockMember2020-12-310000078003us-gaap:AdditionalPaidInCapitalMember2020-12-310000078003us-gaap:TreasuryStockMember2020-12-310000078003us-gaap:RetainedEarningsMember2020-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000078003us-gaap:ParentMember2020-12-310000078003us-gaap:NoncontrollingInterestMember2020-12-310000078003us-gaap:RetainedEarningsMember2021-01-012021-10-030000078003us-gaap:ParentMember2021-01-012021-10-030000078003us-gaap:NoncontrollingInterestMember2021-01-012021-10-030000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-10-030000078003us-gaap:CommonStockMember2021-01-012021-10-030000078003us-gaap:AdditionalPaidInCapitalMember2021-01-012021-10-030000078003us-gaap:TreasuryStockMember2021-01-012021-10-030000078003us-gaap:PreferredStockMember2019-12-310000078003us-gaap:CommonStockMember2019-12-310000078003us-gaap:AdditionalPaidInCapitalMember2019-12-310000078003us-gaap:TreasuryStockMember2019-12-310000078003us-gaap:RetainedEarningsMember2019-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000078003us-gaap:ParentMember2019-12-310000078003us-gaap:NoncontrollingInterestMember2019-12-3100000780032019-12-310000078003us-gaap:RetainedEarningsMember2020-01-012020-09-270000078003us-gaap:ParentMember2020-01-012020-09-270000078003us-gaap:NoncontrollingInterestMember2020-01-012020-09-270000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-270000078003us-gaap:CommonStockMember2020-01-012020-09-270000078003us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-270000078003us-gaap:TreasuryStockMember2020-01-012020-09-270000078003us-gaap:PreferredStockMember2020-01-012020-09-270000078003srt:RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember2020-01-010000078003pfe:ScenarioPreviousAccountingPrincipleMember2021-07-052021-10-030000078003pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember2021-07-052021-10-030000078003pfe:ScenarioPreviousAccountingPrincipleMember2020-06-292020-09-270000078003pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember2020-06-292020-09-270000078003pfe:ScenarioPreviousAccountingPrincipleMember2021-01-012021-10-030000078003pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember2021-01-012021-10-030000078003pfe:ScenarioPreviousAccountingPrincipleMember2020-01-012020-09-270000078003pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember2020-01-012020-09-270000078003pfe:ScenarioPreviousAccountingPrincipleMember2021-10-030000078003pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember2021-10-030000078003pfe:ScenarioPreviousAccountingPrincipleMember2020-12-310000078003pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember2020-12-310000078003us-gaap:AccountsReceivableMember2021-10-030000078003us-gaap:AccountsReceivableMember2020-12-310000078003us-gaap:OtherCurrentLiabilitiesMember2021-10-030000078003us-gaap:OtherCurrentLiabilitiesMember2020-12-310000078003us-gaap:OtherNoncurrentLiabilitiesMember2021-10-030000078003us-gaap:OtherNoncurrentLiabilitiesMember2020-12-310000078003pfe:ViatrisMember2021-10-030000078003pfe:ViatrisMember2020-12-310000078003pfe:ViatrisMember2021-01-012021-04-040000078003us-gaap:SegmentDiscontinuedOperationsMember2021-07-052021-10-030000078003us-gaap:SegmentDiscontinuedOperationsMember2020-06-292020-09-270000078003us-gaap:SegmentDiscontinuedOperationsMember2021-01-012021-10-030000078003us-gaap:SegmentDiscontinuedOperationsMember2020-01-012020-09-270000078003pfe:UpjohnIncAndUpjohnFinanceBVMemberus-gaap:SegmentDiscontinuedOperationsMember2020-06-292020-09-270000078003pfe:UpjohnIncAndUpjohnFinanceBVMemberus-gaap:SegmentDiscontinuedOperationsMember2020-01-012020-09-270000078003pfe:UpjohnFinanceBVMemberus-gaap:SegmentDiscontinuedOperationsMember2020-01-012020-09-270000078003pfe:UpjohnFinanceBVMemberus-gaap:SegmentDiscontinuedOperationsMember2020-06-292020-09-27xbrli:pure0000078003pfe:ConsumerHealthcareJVMember2019-07-310000078003pfe:GSKMemberpfe:ConsumerHealthcareJVMember2019-07-310000078003pfe:ConsumerHealthcareJVMember2021-10-030000078003pfe:ConsumerHealthcareJVMember2020-12-310000078003pfe:ConsumerHealthcareJVMember2021-01-012021-10-030000078003pfe:ConsumerHealthcareJVMember2021-07-052021-10-030000078003pfe:ConsumerHealthcareJVMember2020-06-292020-09-270000078003pfe:ConsumerHealthcareJVMember2020-01-012020-09-270000078003pfe:ConsumerHealthcareJVMember2021-04-012021-06-300000078003pfe:ConsumerHealthcareJVMember2020-04-012020-06-300000078003pfe:ConsumerHealthcareJVMember2020-10-012021-06-300000078003pfe:ConsumerHealthcareJVMember2019-10-012020-06-300000078003pfe:ArvinasIncMemberus-gaap:CollaborativeArrangementMember2021-07-012021-07-310000078003pfe:ArvinasIncMemberus-gaap:CollaborativeArrangementMember2021-09-130000078003pfe:ArvinasIncMemberus-gaap:CollaborativeArrangementMember2021-09-132021-09-13pfe:tradingDay0000078003us-gaap:CollaborativeArrangementMemberpfe:ArvinasIncMember2021-09-132021-09-130000078003pfe:ArvinasIncMemberus-gaap:CollaborativeArrangementMember2021-07-222021-07-220000078003pfe:FocusedCompanyPlanMemberpfe:CorporateEnablingFunctionsMember2021-10-030000078003pfe:FocusedCompanyPlanMemberpfe:GoToMarketModelMember2021-10-030000078003pfe:FocusedCompanyPlanMemberpfe:ManufacturingOptimizationMember2021-10-030000078003pfe:FocusedCompanyPlanMemberpfe:ManufacturingOptimizationMember2021-01-012021-10-030000078003pfe:FocusedCompanyPlanMember2019-10-012021-10-030000078003us-gaap:OtherNonoperatingIncomeExpenseMember2021-07-052021-10-030000078003us-gaap:OtherNonoperatingIncomeExpenseMember2020-06-292020-09-270000078003us-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-10-030000078003us-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-09-270000078003us-gaap:CostOfSalesMember2021-07-052021-10-030000078003us-gaap:CostOfSalesMember2020-06-292020-09-270000078003us-gaap:CostOfSalesMember2021-01-012021-10-030000078003us-gaap:CostOfSalesMember2020-01-012020-09-270000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-052021-10-030000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-06-292020-09-270000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-10-030000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-270000078003us-gaap:ResearchAndDevelopmentExpenseMember2021-07-052021-10-030000078003us-gaap:ResearchAndDevelopmentExpenseMember2020-06-292020-09-270000078003us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-10-030000078003us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-270000078003us-gaap:EmployeeSeveranceMember2020-12-310000078003pfe:AssetImpairmentsMember2020-12-310000078003us-gaap:OtherRestructuringMember2020-12-310000078003us-gaap:EmployeeSeveranceMember2021-01-012021-10-030000078003pfe:AssetImpairmentsMember2021-01-012021-10-030000078003us-gaap:OtherRestructuringMember2021-01-012021-10-030000078003us-gaap:EmployeeSeveranceMember2021-10-030000078003pfe:AssetImpairmentsMember2021-10-030000078003us-gaap:OtherRestructuringMember2021-10-030000078003pfe:BioNTechAndCerevelTherapeuticsLLCMember2021-07-052021-10-030000078003pfe:BioNTechAndCerevelTherapeuticsLLCMember2021-01-012021-10-030000078003pfe:AllogeneMember2020-06-292020-09-270000078003pfe:AllogeneAndBioNTechMember2020-01-012020-09-270000078003pfe:BioNTechMemberus-gaap:CollaborativeArrangementMember2021-01-012021-10-030000078003pfe:CK1AssetsSoldToBiogenIncMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-09-270000078003pfe:PumaTechnologiesMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-270000078003pfe:EliLillyCompanyMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-270000078003pfe:EpiPenMember2021-01-012021-10-030000078003us-gaap:InProcessResearchAndDevelopmentMember2020-01-012020-09-270000078003us-gaap:InProcessResearchAndDevelopmentMember2020-06-292020-09-270000078003us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2020-12-310000078003us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-10-030000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-10-030000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-10-030000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2021-01-012021-10-030000078003us-gaap:AccumulatedTranslationAdjustmentMember2021-10-030000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-10-030000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-10-030000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2021-10-030000078003us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-10-030000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2021-10-030000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2020-12-310000078003us-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2021-10-030000078003us-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2020-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2020-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2021-10-030000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2020-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2021-10-030000078003us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2020-12-310000078003us-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-10-030000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-10-030000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-10-030000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-10-030000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310000078003us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310000078003us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-10-030000078003us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2021-10-030000078003us-gaap:CarryingReportedAmountFairValueDisclosureMember2020-12-310000078003us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2020-12-310000078003us-gaap:ForeignGovernmentDebtSecuritiesMember2021-10-030000078003us-gaap:ForeignGovernmentDebtSecuritiesMember2020-12-310000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-10-030000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000078003us-gaap:CorporateDebtSecuritiesMember2021-10-030000078003us-gaap:CorporateDebtSecuritiesMember2020-12-310000078003us-gaap:BankTimeDepositsMember2021-10-030000078003us-gaap:BankTimeDepositsMember2020-12-310000078003us-gaap:SeniorNotesMemberpfe:SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member2021-10-030000078003us-gaap:UnsecuredDebtMember2021-10-030000078003us-gaap:UnsecuredDebtMember2020-12-310000078003us-gaap:ForeignExchangeContractMember2021-01-012021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000078003us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-10-030000078003us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000078003us-gaap:DesignatedAsHedgingInstrumentMember2021-10-030000078003us-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-12-310000078003us-gaap:SalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-10-030000078003us-gaap:SalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003us-gaap:CashFlowHedgingMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003us-gaap:CashFlowHedgingMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003us-gaap:InterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003us-gaap:InterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003us-gaap:NetInvestmentHedgingMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003us-gaap:NetInvestmentHedgingMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003pfe:ForeignCurrencyShortTermBorrowingsMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003pfe:ForeignCurrencyShortTermBorrowingsMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003pfe:ForeignCurrencyShortTermBorrowingsMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003pfe:ForeignCurrencyShortTermBorrowingsMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003pfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003pfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberpfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberpfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2021-07-052021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2020-06-292020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMember2021-07-052021-10-030000078003pfe:OtherIncomeDeductionsAndCostOfSalesMember2020-06-292020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003us-gaap:CashFlowHedgingMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003us-gaap:CashFlowHedgingMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003us-gaap:InterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003us-gaap:InterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003us-gaap:NetInvestmentHedgingMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003us-gaap:NetInvestmentHedgingMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003pfe:ForeignCurrencyShortTermBorrowingsMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003pfe:ForeignCurrencyShortTermBorrowingsMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003pfe:ForeignCurrencyShortTermBorrowingsMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003pfe:ForeignCurrencyShortTermBorrowingsMemberpfe:OtherIncomeDeductionsAndCostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003pfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003pfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberpfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003pfe:OtherIncomeDeductionsAndCostOfSalesMemberpfe:ForeignCurrencyDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2021-01-012021-10-030000078003us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2020-01-012020-09-270000078003pfe:OtherIncomeDeductionsAndCostOfSalesMember2021-01-012021-10-030000078003pfe:OtherIncomeDeductionsAndCostOfSalesMember2020-01-012020-09-270000078003us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-07-052021-10-030000078003us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-10-030000078003us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-06-292020-09-270000078003us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-270000078003pfe:ForeignCurrencyDebtMember2021-10-030000078003pfe:ForeignCurrencyDebtMember2020-12-310000078003us-gaap:LongTermDebtMember2021-10-030000078003us-gaap:LongTermDebtMember2020-12-310000078003pfe:ComirnatyMemberpfe:BioNTechMemberus-gaap:CollaborativeArrangementMember2021-10-030000078003pfe:ComirnatyMemberpfe:BioNTechMemberus-gaap:CollaborativeArrangementMember2020-12-310000078003us-gaap:DevelopedTechnologyRightsMember2021-10-030000078003us-gaap:DevelopedTechnologyRightsMember2020-12-310000078003us-gaap:TradeNamesMember2021-10-030000078003us-gaap:TradeNamesMember2020-12-310000078003pfe:LicensingAgreementsAndOtherMember2021-10-030000078003pfe:LicensingAgreementsAndOtherMember2020-12-310000078003us-gaap:TradeNamesMember2021-10-030000078003us-gaap:TradeNamesMember2020-12-310000078003us-gaap:InProcessResearchAndDevelopmentMember2021-10-030000078003us-gaap:InProcessResearchAndDevelopmentMember2020-12-310000078003pfe:LicensingAgreementsAndOtherMember2021-10-030000078003pfe:LicensingAgreementsAndOtherMember2020-12-310000078003pfe:ComirnatyMemberpfe:BioNTechMemberus-gaap:DevelopedTechnologyRightsMember2021-01-012021-10-030000078003us-gaap:FiniteLivedIntangibleAssetsMember2021-07-052021-10-030000078003us-gaap:FiniteLivedIntangibleAssetsMember2020-06-292020-09-270000078003us-gaap:FiniteLivedIntangibleAssetsMember2021-01-012021-10-030000078003us-gaap:FiniteLivedIntangibleAssetsMember2020-01-012020-09-270000078003us-gaap:PensionPlansDefinedBenefitMembercountry:US2021-07-052021-10-030000078003us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-06-292020-09-270000078003us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-07-052021-10-030000078003us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-06-292020-09-270000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-052021-10-030000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-06-292020-09-270000078003us-gaap:PensionPlansDefinedBenefitMembercountry:US2021-01-012021-10-030000078003us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-01-012020-09-270000078003us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-01-012021-10-030000078003us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-01-012020-09-270000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-10-030000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-09-27pfe:patent0000078003pfe:PneumococcalVaccinePatentInfringementMember2017-01-012017-12-310000078003pfe:PneumococcalVaccinePatentInfringementMember2021-01-012021-10-030000078003pfe:OtherPatentInfringementMember2021-01-012021-10-030000078003pfe:PatentInfringementMemberpfe:PfizerVersusGenericCompaniesMember2019-01-012019-12-31pfe:defendant0000078003pfe:PatentInfringementMemberpfe:EliquisMemberpfe:PfizerandBMSVersusSeveralGenericManufacturersMemberus-gaap:PendingLitigationMember2017-01-012017-12-31pfe:manufacturer0000078003pfe:DocetaxelMemberus-gaap:PendingLitigationMemberpfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember2018-01-012018-12-31pfe:classAction0000078003pfe:ArraySecuritiesLitigationMember2017-01-012017-12-310000078003pfe:ZantacLitigationMember2020-02-012020-02-29pfe:lagoon0000078003pfe:EnvironmentalRemediationLitigationMember2013-01-012013-12-310000078003pfe:EnvironmentalRemediationLitigationMember2018-01-012018-12-310000078003pfe:EnvironmentalRemediationLitigationMember2021-09-012021-09-300000078003pfe:EpiPenMember2021-07-012021-07-310000078003country:US2021-07-052021-10-030000078003country:US2020-06-292020-09-270000078003country:US2021-01-012021-10-030000078003country:US2020-01-012020-09-270000078003pfe:DevelopedEuropeMember2021-07-052021-10-030000078003pfe:DevelopedEuropeMember2020-06-292020-09-270000078003pfe:DevelopedEuropeMember2021-01-012021-10-030000078003pfe:DevelopedEuropeMember2020-01-012020-09-270000078003pfe:DevelopedRestOfWorldMember2021-07-052021-10-030000078003pfe:DevelopedRestOfWorldMember2020-06-292020-09-270000078003pfe:DevelopedRestOfWorldMember2021-01-012021-10-030000078003pfe:DevelopedRestOfWorldMember2020-01-012020-09-270000078003pfe:EmergingMarketsMember2021-07-052021-10-030000078003pfe:EmergingMarketsMember2020-06-292020-09-270000078003pfe:EmergingMarketsMember2021-01-012021-10-030000078003pfe:EmergingMarketsMember2020-01-012020-09-270000078003us-gaap:SalesRevenueNetMemberpfe:ComirnatyMemberpfe:GovernmentAndGovernmentSponsoredMemberus-gaap:CustomerConcentrationRiskMember2021-07-052021-10-030000078003us-gaap:SalesRevenueNetMemberpfe:ComirnatyMemberpfe:GovernmentAndGovernmentSponsoredMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-10-030000078003pfe:ComirnatyMemberus-gaap:AccountsReceivableMemberpfe:GovernmentAndGovernmentSponsoredMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-10-030000078003pfe:VaccinesMember2021-07-052021-10-030000078003pfe:VaccinesMember2020-06-292020-09-270000078003pfe:VaccinesMember2021-01-012021-10-030000078003pfe:VaccinesMember2020-01-012020-09-270000078003pfe:ComirnatyMemberpfe:VaccinesMember2021-07-052021-10-030000078003pfe:ComirnatyMemberpfe:VaccinesMember2020-06-292020-09-270000078003pfe:ComirnatyMemberpfe:VaccinesMember2021-01-012021-10-030000078003pfe:ComirnatyMemberpfe:VaccinesMember2020-01-012020-09-270000078003pfe:PrevnarPrevenarFamilyMemberpfe:VaccinesMember2021-07-052021-10-030000078003pfe:PrevnarPrevenarFamilyMemberpfe:VaccinesMember2020-06-292020-09-270000078003pfe:PrevnarPrevenarFamilyMemberpfe:VaccinesMember2021-01-012021-10-030000078003pfe:PrevnarPrevenarFamilyMemberpfe:VaccinesMember2020-01-012020-09-270000078003pfe:VaccinesMemberpfe:FSMEIMMUNTicoVacMember2021-07-052021-10-030000078003pfe:VaccinesMemberpfe:FSMEIMMUNTicoVacMember2020-06-292020-09-270000078003pfe:VaccinesMemberpfe:FSMEIMMUNTicoVacMember2021-01-012021-10-030000078003pfe:VaccinesMemberpfe:FSMEIMMUNTicoVacMember2020-01-012020-09-270000078003pfe:NimenrixMemberpfe:VaccinesMember2021-07-052021-10-030000078003pfe:NimenrixMemberpfe:VaccinesMember2020-06-292020-09-270000078003pfe:NimenrixMemberpfe:VaccinesMember2021-01-012021-10-030000078003pfe:NimenrixMemberpfe:VaccinesMember2020-01-012020-09-270000078003pfe:VaccinesMemberpfe:TrumenbaMember2021-07-052021-10-030000078003pfe:VaccinesMemberpfe:TrumenbaMember2020-06-292020-09-270000078003pfe:VaccinesMemberpfe:TrumenbaMember2021-01-012021-10-030000078003pfe:VaccinesMemberpfe:TrumenbaMember2020-01-012020-09-270000078003pfe:OtherVaccinesProductsMemberpfe:VaccinesMember2021-07-052021-10-030000078003pfe:OtherVaccinesProductsMemberpfe:VaccinesMember2020-06-292020-09-270000078003pfe:OtherVaccinesProductsMemberpfe:VaccinesMember2021-01-012021-10-030000078003pfe:OtherVaccinesProductsMemberpfe:VaccinesMember2020-01-012020-09-270000078003pfe:OncologyMember2021-07-052021-10-030000078003pfe:OncologyMember2020-06-292020-09-270000078003pfe:OncologyMember2021-01-012021-10-030000078003pfe:OncologyMember2020-01-012020-09-270000078003pfe:IbranceMemberpfe:OncologyMember2021-07-052021-10-030000078003pfe:IbranceMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:IbranceMemberpfe:OncologyMember2021-01-012021-10-030000078003pfe:IbranceMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:XtandiAllianceRevenuesMemberpfe:OncologyMember2021-07-052021-10-030000078003pfe:XtandiAllianceRevenuesMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:XtandiAllianceRevenuesMemberpfe:OncologyMember2021-01-012021-10-030000078003pfe:XtandiAllianceRevenuesMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:InlytaMemberpfe:OncologyMember2021-07-052021-10-030000078003pfe:InlytaMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:InlytaMemberpfe:OncologyMember2021-01-012021-10-030000078003pfe:InlytaMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:OncologyMemberpfe:SutentMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:SutentMember2020-06-292020-09-270000078003pfe:OncologyMemberpfe:SutentMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:SutentMember2020-01-012020-09-270000078003pfe:BosulifMemberpfe:OncologyMember2021-07-052021-10-030000078003pfe:BosulifMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:BosulifMemberpfe:OncologyMember2021-01-012021-10-030000078003pfe:BosulifMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:XalkoriMemberpfe:OncologyMember2021-07-052021-10-030000078003pfe:XalkoriMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:XalkoriMemberpfe:OncologyMember2021-01-012021-10-030000078003pfe:XalkoriMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:RuxienceMemberpfe:OncologyMember2021-07-052021-10-030000078003pfe:RuxienceMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:RuxienceMemberpfe:OncologyMember2021-01-012021-10-030000078003pfe:RuxienceMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:OncologyMemberpfe:RetacritMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:RetacritMember2020-06-292020-09-270000078003pfe:OncologyMemberpfe:RetacritMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:RetacritMember2020-01-012020-09-270000078003pfe:ZirabevMemberpfe:OncologyMember2021-07-052021-10-030000078003pfe:ZirabevMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:ZirabevMemberpfe:OncologyMember2021-01-012021-10-030000078003pfe:ZirabevMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:LorbrenaMemberpfe:OncologyMember2021-07-052021-10-030000078003pfe:LorbrenaMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:LorbrenaMemberpfe:OncologyMember2021-01-012021-10-030000078003pfe:LorbrenaMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:OncologyMemberpfe:AromasinMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:AromasinMember2020-06-292020-09-270000078003pfe:OncologyMemberpfe:AromasinMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:AromasinMember2020-01-012020-09-270000078003pfe:OncologyMemberpfe:BesponsaMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BesponsaMember2020-06-292020-09-270000078003pfe:OncologyMemberpfe:BesponsaMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BesponsaMember2020-01-012020-09-270000078003pfe:BraftoviMemberpfe:OncologyMember2021-07-052021-10-030000078003pfe:BraftoviMemberpfe:OncologyMember2020-06-292020-09-270000078003pfe:BraftoviMemberpfe:OncologyMember2021-01-012021-10-030000078003pfe:BraftoviMemberpfe:OncologyMember2020-01-012020-09-270000078003pfe:OncologyMemberpfe:BavencioAllianceRevenuesMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:BavencioAllianceRevenuesMember2020-06-292020-09-270000078003pfe:OncologyMemberpfe:BavencioAllianceRevenuesMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:BavencioAllianceRevenuesMember2020-01-012020-09-270000078003pfe:OncologyMemberpfe:MektoviMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:MektoviMember2020-06-292020-09-270000078003pfe:OncologyMemberpfe:MektoviMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:MektoviMember2020-01-012020-09-270000078003pfe:OncologyMemberpfe:OtherOncologyProductsMember2021-07-052021-10-030000078003pfe:OncologyMemberpfe:OtherOncologyProductsMember2020-06-292020-09-270000078003pfe:OncologyMemberpfe:OtherOncologyProductsMember2021-01-012021-10-030000078003pfe:OncologyMemberpfe:OtherOncologyProductsMember2020-01-012020-09-270000078003pfe:InternalMedicineMember2021-07-052021-10-030000078003pfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:InternalMedicineMember2021-01-012021-10-030000078003pfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:EliquisMemberpfe:InternalMedicineMember2021-07-052021-10-030000078003pfe:EliquisMemberpfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:EliquisMemberpfe:InternalMedicineMember2021-01-012021-10-030000078003pfe:EliquisMemberpfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:PremarinFamilyMemberpfe:InternalMedicineMember2021-07-052021-10-030000078003pfe:PremarinFamilyMemberpfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:PremarinFamilyMemberpfe:InternalMedicineMember2021-01-012021-10-030000078003pfe:PremarinFamilyMemberpfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:InternalMedicineMemberpfe:ChantixChampixMember2021-07-052021-10-030000078003pfe:InternalMedicineMemberpfe:ChantixChampixMember2020-06-292020-09-270000078003pfe:InternalMedicineMemberpfe:ChantixChampixMember2021-01-012021-10-030000078003pfe:InternalMedicineMemberpfe:ChantixChampixMember2020-01-012020-09-270000078003pfe:BMP2Memberpfe:InternalMedicineMember2021-07-052021-10-030000078003pfe:BMP2Memberpfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:BMP2Memberpfe:InternalMedicineMember2021-01-012021-10-030000078003pfe:BMP2Memberpfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:InternalMedicineMemberpfe:ToviazMember2021-07-052021-10-030000078003pfe:InternalMedicineMemberpfe:ToviazMember2020-06-292020-09-270000078003pfe:InternalMedicineMemberpfe:ToviazMember2021-01-012021-10-030000078003pfe:InternalMedicineMemberpfe:ToviazMember2020-01-012020-09-270000078003pfe:PristiqMemberpfe:InternalMedicineMember2021-07-052021-10-030000078003pfe:PristiqMemberpfe:InternalMedicineMember2020-06-292020-09-270000078003pfe:PristiqMemberpfe:InternalMedicineMember2021-01-012021-10-030000078003pfe:PristiqMemberpfe:InternalMedicineMember2020-01-012020-09-270000078003pfe:InternalMedicineMemberpfe:AllOtherInternalMedicineMember2021-07-052021-10-030000078003pfe:InternalMedicineMemberpfe:AllOtherInternalMedicineMember2020-06-292020-09-270000078003pfe:InternalMedicineMemberpfe:AllOtherInternalMedicineMember2021-01-012021-10-030000078003pfe:InternalMedicineMemberpfe:AllOtherInternalMedicineMember2020-01-012020-09-270000078003pfe:HospitalMember2021-07-052021-10-030000078003pfe:HospitalMember2020-06-292020-09-270000078003pfe:HospitalMember2021-01-012021-10-030000078003pfe:HospitalMember2020-01-012020-09-270000078003pfe:SulperazonMemberpfe:HospitalMember2021-07-052021-10-030000078003pfe:SulperazonMemberpfe:HospitalMember2020-06-292020-09-270000078003pfe:SulperazonMemberpfe:HospitalMember2021-01-012021-10-030000078003pfe:SulperazonMemberpfe:HospitalMember2020-01-012020-09-270000078003pfe:MedrolMemberpfe:HospitalMember2021-07-052021-10-030000078003pfe:MedrolMemberpfe:HospitalMember2020-06-292020-09-270000078003pfe:MedrolMemberpfe:HospitalMember2021-01-012021-10-030000078003pfe:MedrolMemberpfe:HospitalMember2020-01-012020-09-270000078003pfe:ZaviceftaMemberpfe:HospitalMember2021-07-052021-10-030000078003pfe:ZaviceftaMemberpfe:HospitalMember2020-06-292020-09-270000078003pfe:ZaviceftaMemberpfe:HospitalMember2021-01-012021-10-030000078003pfe:ZaviceftaMemberpfe:HospitalMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:EpiPenMember2021-07-052021-10-030000078003pfe:HospitalMemberpfe:EpiPenMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:EpiPenMember2021-01-012021-10-030000078003pfe:HospitalMemberpfe:EpiPenMember2020-01-012020-09-270000078003pfe:FragminMemberpfe:HospitalMember2021-07-052021-10-030000078003pfe:FragminMemberpfe:HospitalMember2020-06-292020-09-270000078003pfe:FragminMemberpfe:HospitalMember2021-01-012021-10-030000078003pfe:FragminMemberpfe:HospitalMember2020-01-012020-09-270000078003pfe:VfendMemberpfe:HospitalMember2021-07-052021-10-030000078003pfe:VfendMemberpfe:HospitalMember2020-06-292020-09-270000078003pfe:VfendMemberpfe:HospitalMember2021-01-012021-10-030000078003pfe:VfendMemberpfe:HospitalMember2020-01-012020-09-270000078003pfe:ZithromaxZmaxMemberpfe:HospitalMember2021-07-052021-10-030000078003pfe:ZithromaxZmaxMemberpfe:HospitalMember2020-06-292020-09-270000078003pfe:ZithromaxZmaxMemberpfe:HospitalMember2021-01-012021-10-030000078003pfe:ZithromaxZmaxMemberpfe:HospitalMember2020-01-012020-09-270000078003pfe:TygacilMemberpfe:HospitalMember2021-07-052021-10-030000078003pfe:TygacilMemberpfe:HospitalMember2020-06-292020-09-270000078003pfe:TygacilMemberpfe:HospitalMember2021-01-012021-10-030000078003pfe:TygacilMemberpfe:HospitalMember2020-01-012020-09-270000078003pfe:PrecedexMemberpfe:HospitalMember2021-07-052021-10-030000078003pfe:PrecedexMemberpfe:HospitalMember2020-06-292020-09-270000078003pfe:PrecedexMemberpfe:HospitalMember2021-01-012021-10-030000078003pfe:PrecedexMemberpfe:HospitalMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:ZyvoxMember2021-07-052021-10-030000078003pfe:HospitalMemberpfe:ZyvoxMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:ZyvoxMember2021-01-012021-10-030000078003pfe:HospitalMemberpfe:ZyvoxMember2020-01-012020-09-270000078003pfe:IVIgProductsMemberpfe:HospitalMember2021-07-052021-10-030000078003pfe:IVIgProductsMemberpfe:HospitalMember2020-06-292020-09-270000078003pfe:IVIgProductsMemberpfe:HospitalMember2021-01-012021-10-030000078003pfe:IVIgProductsMemberpfe:HospitalMember2020-01-012020-09-270000078003pfe:HospitalMemberpfe:PfizerCentreOneMember2021-07-052021-10-030000078003pfe:HospitalMemberpfe:PfizerCentreOneMember2020-06-292020-09-270000078003pfe:HospitalMemberpfe:PfizerCentreOneMember2021-01-012021-10-030000078003pfe:HospitalMemberpfe:PfizerCentreOneMember2020-01-012020-09-270000078003pfe:OtherAntiinfectivesMemberpfe:HospitalMember2021-07-052021-10-030000078003pfe:OtherAntiinfectivesMemberpfe:HospitalMember2020-06-292020-09-270000078003pfe:OtherAntiinfectivesMemberpfe:HospitalMember2021-01-012021-10-030000078003pfe:OtherAntiinfectivesMemberpfe:HospitalMember2020-01-012020-09-270000078003pfe:OtherHospitalProductsMemberpfe:HospitalMember2021-07-052021-10-030000078003pfe:OtherHospitalProductsMemberpfe:HospitalMember2020-06-292020-09-270000078003pfe:OtherHospitalProductsMemberpfe:HospitalMember2021-01-012021-10-030000078003pfe:OtherHospitalProductsMemberpfe:HospitalMember2020-01-012020-09-270000078003pfe:InflammationandImmunologyMember2021-07-052021-10-030000078003pfe:InflammationandImmunologyMember2020-06-292020-09-270000078003pfe:InflammationandImmunologyMember2021-01-012021-10-030000078003pfe:InflammationandImmunologyMember2020-01-012020-09-270000078003pfe:InflammationandImmunologyMemberpfe:XeljanzMember2021-07-052021-10-030000078003pfe:InflammationandImmunologyMemberpfe:XeljanzMember2020-06-292020-09-270000078003pfe:InflammationandImmunologyMemberpfe:XeljanzMember2021-01-012021-10-030000078003pfe:InflammationandImmunologyMemberpfe:XeljanzMember2020-01-012020-09-270000078003pfe:InflammationandImmunologyMemberpfe:EnbrelMember2021-07-052021-10-030000078003pfe:InflammationandImmunologyMemberpfe:EnbrelMember2020-06-292020-09-270000078003pfe:InflammationandImmunologyMemberpfe:EnbrelMember2021-01-012021-10-030000078003pfe:InflammationandImmunologyMemberpfe:EnbrelMember2020-01-012020-09-270000078003pfe:InflectraRemsimaMemberpfe:InflammationandImmunologyMember2021-07-052021-10-030000078003pfe:InflectraRemsimaMemberpfe:InflammationandImmunologyMember2020-06-292020-09-270000078003pfe:InflectraRemsimaMemberpfe:InflammationandImmunologyMember2021-01-012021-10-030000078003pfe:InflectraRemsimaMemberpfe:InflammationandImmunologyMember2020-01-012020-09-270000078003pfe:InflammationandImmunologyMemberpfe:AllOtherInflammationandImmunologyProductsMember2021-07-052021-10-030000078003pfe:InflammationandImmunologyMemberpfe:AllOtherInflammationandImmunologyProductsMember2020-06-292020-09-270000078003pfe:InflammationandImmunologyMemberpfe:AllOtherInflammationandImmunologyProductsMember2021-01-012021-10-030000078003pfe:InflammationandImmunologyMemberpfe:AllOtherInflammationandImmunologyProductsMember2020-01-012020-09-270000078003pfe:RareDiseaseMember2021-07-052021-10-030000078003pfe:RareDiseaseMember2020-06-292020-09-270000078003pfe:RareDiseaseMember2021-01-012021-10-030000078003pfe:RareDiseaseMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:VyndaqelMember2021-07-052021-10-030000078003pfe:RareDiseaseMemberpfe:VyndaqelMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:VyndaqelMember2021-01-012021-10-030000078003pfe:RareDiseaseMemberpfe:VyndaqelMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:BeneFIXMember2021-07-052021-10-030000078003pfe:RareDiseaseMemberpfe:BeneFIXMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:BeneFIXMember2021-01-012021-10-030000078003pfe:RareDiseaseMemberpfe:BeneFIXMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:GenotropinMember2021-07-052021-10-030000078003pfe:RareDiseaseMemberpfe:GenotropinMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:GenotropinMember2021-01-012021-10-030000078003pfe:RareDiseaseMemberpfe:GenotropinMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:ReFactoAfXynthaMember2021-07-052021-10-030000078003pfe:RareDiseaseMemberpfe:ReFactoAfXynthaMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:ReFactoAfXynthaMember2021-01-012021-10-030000078003pfe:RareDiseaseMemberpfe:ReFactoAfXynthaMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:SomavertMember2021-07-052021-10-030000078003pfe:RareDiseaseMemberpfe:SomavertMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:SomavertMember2021-01-012021-10-030000078003pfe:RareDiseaseMemberpfe:SomavertMember2020-01-012020-09-270000078003pfe:RareDiseaseMemberpfe:AllOtherRareDiseaseProductsMember2021-07-052021-10-030000078003pfe:RareDiseaseMemberpfe:AllOtherRareDiseaseProductsMember2020-06-292020-09-270000078003pfe:RareDiseaseMemberpfe:AllOtherRareDiseaseProductsMember2021-01-012021-10-030000078003pfe:RareDiseaseMemberpfe:AllOtherRareDiseaseProductsMember2020-01-012020-09-270000078003pfe:TotalAllianceBiopharmaceuticalsMember2021-07-052021-10-030000078003pfe:TotalAllianceBiopharmaceuticalsMember2020-06-292020-09-270000078003pfe:TotalAllianceBiopharmaceuticalsMember2021-01-012021-10-030000078003pfe:TotalAllianceBiopharmaceuticalsMember2020-01-012020-09-270000078003pfe:TotalBiosimilarsMember2021-07-052021-10-030000078003pfe:TotalBiosimilarsMember2020-06-292020-09-270000078003pfe:TotalBiosimilarsMember2021-01-012021-10-030000078003pfe:TotalBiosimilarsMember2020-01-012020-09-270000078003pfe:TotalSterileInjectablePharmaceuticalsMember2021-07-052021-10-030000078003pfe:TotalSterileInjectablePharmaceuticalsMember2020-06-292020-09-270000078003pfe:TotalSterileInjectablePharmaceuticalsMember2021-01-012021-10-030000078003pfe:TotalSterileInjectablePharmaceuticalsMember2020-01-012020-09-270000078003pfe:BioNTechMemberpfe:HospitalMemberpfe:PfizerCentreOneMember2021-07-052021-10-030000078003pfe:BioNTechMemberpfe:HospitalMemberpfe:PfizerCentreOneMember2021-01-012021-10-030000078003pfe:ComirnatyMemberpfe:GovernmentAndGovernmentSponsoredMember2021-10-030000078003pfe:ComirnatyMemberpfe:GovernmentAndGovernmentSponsoredMember2020-12-310000078003pfe:ComirnatyMemberpfe:GovernmentAndGovernmentSponsoredMember2021-07-052021-10-030000078003pfe:ComirnatyMemberpfe:GovernmentAndGovernmentSponsoredMember2021-01-012021-10-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 3, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______


COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State of Incorporation)(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York  10017
(Address of principal executive offices)  (zip code)
(212) 733-2323
(Registrant’s telephone number)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.05 par valuePFENew York Stock Exchange
0.250% Notes due 2022PFE22New York Stock Exchange
1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x              Accelerated filer                 Non-accelerated filer            Smaller reporting company      Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YesNo
x

At November 8, 2021, 5,612,866,598 shares of the issuer’s voting common stock were outstanding.



TABLE OF CONTENTS
Page
 
 
Item 2.
 
 
 
 
 
 
Item 3. 
Defaults Upon Senior SecuritiesN/A
Item 4. 
Mine Safety DisclosuresN/A
Item 5. 
Other InformationN/A
 
N/A = Not Applicable
2


DEFINED TERMS

Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 29, 2021 and August 23, 2020, and for U.S. subsidiaries is as of and for the three and nine months ended October 3, 2021 and September 27, 2020. References to “Notes” in this Form 10-Q are to the notes to the condensed or consolidated financial statements in this Form 10-Q or our 2020 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined:
2020 Form 10-KAnnual Report on Form 10-K for the fiscal year ended December 31, 2020
ACIPAdvisory Committee on Immunization Practices
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
AllogeneAllogene Therapeutics, Inc.
ArrayArray BioPharma Inc.
ArvinasArvinas, Inc.
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
BioNTechBioNTech SE
BLABiologics License Application
BMSBristol-Myers Squibb Company
BNT162b2Pfizer BioNTech COVID-19 Vaccine
ComirnatyPfizer-BioNTech COVID-19 Vaccine
BODBoard of Directors
CDCU.S. Centers for Disease Control and Prevention
CMA
conditional marketing authorization
Consumer Healthcare JVGSK Consumer Healthcare JV
COVID-19novel coronavirus disease of 2019
Developed Europe
Includes the following markets: Western Europe, Scandinavian countries and Finland
Developed MarketsIncludes the following markets: U.S., Developed Europe, Japan, Canada, South Korea, Australia and New Zealand
Developed Rest of World
Includes the following markets: Japan, Canada, South Korea, Australia and New Zealand
EMAEuropean Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Central Europe, Eastern Europe, the Middle East, Africa and Turkey
EPSearnings per share
EUEuropean Union
EUAemergency use authorization
Exchange ActSecurities Exchange Act of 1934, as amended
FDAU.S. Food and Drug Administration
Form 10-QQuarterly Report on Form 10-Q for the quarterly period ended October 3, 2021
GAAPGenerally Accepted Accounting Principles
GISTgastrointestinal stromal tumors
GSKGlaxoSmithKline plc
HospiraHospira, Inc.
IPR&Din-process research and development
IRSU.S. Internal Revenue Service
JVjoint venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LIBORLondon Interbank Offered Rate
LillyEli Lilly & Company
LOEloss of exclusivity
MCOmanaged care organization
mCRCmetastatic colorectal cancer
mCRPC
metastatic castration-resistant prostate cancer
mCSPC
metastatic castration-sensitive prostate cancer
MD&AManagement’s Discussion and Analysis of Financial Condition and Results of Operations
MeridianMeridian Medical Technologies, Inc.
3


MTMmark-to-market
MylanMylan N.V.
Mylan-Japan collaborationa pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan that terminated on December 21, 2020
MyovantMyovant Sciences Ltd.
nmCRPC
non-metastatic castration-resistant prostate cancer
NSCLCnon-small cell lung cancer
OPKOOPKO Health, Inc.
OTCover-the-counter
PaxlovidPF-07321332 (SARS-CoV-2 3CL protease inhibitor (oral anti-viral)); ritonavir
PBMpharmacy benefit manager
PDUFAPrescription Drug User Fee Act
PGSPfizer Global Supply
PharmaciaPharmacia Corporation
PsApsoriatic arthritis
QTDQuarter-to-date or three months ended
RArheumatoid arthritis
RCCrenal cell carcinoma
R&Dresearch and development
SandozSandoz, Inc., a division of Novartis AG
SECU.S. Securities and Exchange Commission
SI&Aselling, informational and administrative
UCulcerative colitis
U.K.United Kingdom
U.S.United States
Upjohn BusinessPfizer’s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris
ValnevaValneva SE
ViatrisViatris Inc.
YTD
Year-to-date or nine months ended
This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.
The information contained on our website, our Facebook, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.
4


PART I.  FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
 Three Months EndedNine Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)October 3,
2021
September 27,
2020
October 3,
2021
September 27,
2020
Revenues$24,094 $10,277 $57,653 $30,224 
Costs and expenses:
Cost of sales(a)
9,973 2,007 21,232 5,773 
Selling, informational and administrative expenses(a)
2,905 2,658 8,617 7,858 
Research and development expenses(a)
3,447 2,300 7,920 6,050 
Amortization of intangible assets981 862 2,784 2,579 
Restructuring charges and certain acquisition-related costs
646 2 668 417 
(Gain) on completion of Consumer Healthcare JV transaction
   (6)
Other (income)/deductions––net
(1,696)1,878 (3,697)1,114 
Income from continuing operations before provision/(benefit) for taxes on income7,836 570 20,128 6,438 
Provision/(benefit) for taxes on income(331)(347)1,518 434 
Income from continuing operations8,167 917 18,610 6,004 
Income/(loss) from discontinued operations––net of tax(9)560 24 2,334 
Net income before allocation to noncontrolling interests8,159 1,477 18,633 8,338 
Less: Net income attributable to noncontrolling interests12 8 47 25 
Net income attributable to Pfizer Inc. common shareholders$8,146 $1,469 $18,586 $8,313 
Earnings per common share––basic:
    
Income from continuing operations attributable to Pfizer Inc. common shareholders$1.45 $0.16 $3.32 $1.08 
Income/(loss) from discontinued operations––net of tax 0.10  0.42 
Net income attributable to Pfizer Inc. common shareholders$1.45 $0.26 $3.32 $1.50 
Earnings per common share––diluted:
    
Income from continuing operations attributable to Pfizer Inc. common shareholders$1.42 $0.16 $3.26 $1.06 
Income/(loss) from discontinued operations––net of tax 0.10  0.42 
Net income attributable to Pfizer Inc. common shareholders$1.42 $0.26 $3.27 $1.48 
Weighted-average shares––basic5,609 5,557 5,597 5,552 
Weighted-average shares––diluted5,725 5,633 5,688 5,622 
(a)Exclusive of amortization of intangible assets, except as disclosed in Note 9 in this Form 10-Q and Note 1L in our 2020 Form 10-K.
See Accompanying Notes.
5


PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
 Three Months EndedNine Months Ended
(MILLIONS)October 3,
2021
September 27,
2020
October 3,
2021
September 27,
2020
Net income before allocation to noncontrolling interests$8,159 $1,477 $18,633 $8,338 
Foreign currency translation adjustments, net(866)1,403 (366)(27)
Unrealized holding gains/(losses) on derivative financial instruments, net213 (372)179 (661)
Reclassification adjustments for (gains)/losses included in net income(a)
48 143 286 (25)
 261 (230)464 (685)
Unrealized holding gains/(losses) on available-for-sale securities, net(266)239 (128)231 
Reclassification adjustments for (gains)/losses included in net income(b)
9 (85)(172)(25)
 (257)155 (300)205 
Reclassification adjustments related to amortization of prior service costs and other, net(39)(45)(119)(134)
Reclassification adjustments related to curtailments of prior service costs and other, net(59) (59) 
Other2 (3)(3)1 
 (97)(47)(181)(133)
Other comprehensive income/(loss), before tax(959)1,280 (382)(640)
Tax provision/(benefit) on other comprehensive income/(loss)(65)(19)(44)(311)
Other comprehensive income/(loss) before allocation to noncontrolling interests$(894)$1,299 $(338)$(329)
Comprehensive income/(loss) before allocation to noncontrolling interests$7,265 $2,776 $18,296 $8,009 
Less: Comprehensive income/(loss) attributable to noncontrolling interests9 11 48 16 
Comprehensive income/(loss) attributable to Pfizer Inc.$7,256 $2,766 $18,248 $7,993 
(a)Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
(b)Reclassified into Other (income)/deductions—net.
See Accompanying Notes.
6


PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS)October 3,
2021
December 31, 2020
(Unaudited)
Assets
Cash and cash equivalents$1,966 $1,784 
Short-term investments27,730 10,437 
Trade accounts receivable, less allowance for doubtful accounts: 2021—$494; 2020—$508
11,897 7,930 
Inventories8,640 8,046 
Current tax assets3,877 3,264 
Other current assets3,790 3,605 
Total current assets57,900 35,067 
Equity-method investments16,349 16,856 
Long-term investments5,248 3,406 
Property, plant and equipment, less accumulated depreciation: 2021—$15,403; 2020—$14,812
14,436 13,900 
Identifiable intangible assets26,306 28,471 
Goodwill49,489 49,577 
Noncurrent deferred tax assets and other noncurrent tax assets2,755 2,383 
Other noncurrent assets6,705 4,569 
Total assets$179,188 $154,229 
Liabilities and Equity  
Short-term borrowings, including current portion of long-term debt: 2021—$2,663; 2020—$2,002
$3,629 $2,703 
Trade accounts payable4,698 4,309 
Dividends payable2,191 2,162 
Income taxes payable4,496 1,049 
Accrued compensation and related items2,571 3,058 
Deferred revenues3,529 1,113 
Other current liabilities20,690 11,527 
Total current liabilities41,803 25,920 
Long-term debt36,250 37,133 
Pension benefit obligations3,676 4,766 
Postretirement benefit obligations627 645 
Noncurrent deferred tax liabilities328 4,063 
Other taxes payable11,336 11,560 
Other noncurrent liabilities9,201 6,669 
Total liabilities103,221 90,756 
Commitments and Contingencies
Common stock473 470 
Additional paid-in capital89,973 88,674 
Treasury stock(111,359)(110,988)
Retained earnings102,252 90,392 
Accumulated other comprehensive loss(5,649)(5,310)
Total Pfizer Inc. shareholders’ equity75,691 63,238 
Equity attributable to noncontrolling interests275 235 
Total equity75,967 63,473 
Total liabilities and equity$179,188 $154,229 
See Accompanying Notes.
7


PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
PFIZER INC. SHAREHOLDERS
Preferred StockCommon StockTreasury Stock
(MILLIONS, EXCEPT PREFERRED SHARES)SharesStated ValueSharesPar ValueAdd’l
Paid-In Capital
SharesCostRetained EarningsAccum. Other Comp.
Loss
Share-
holders’ Equity
Non-controlling interestsTotal Equity
Balance, July 4, 2021
 $ 9,450 $472 $89,336 (3,851)$(111,356)$96,346 $(4,758)$70,042 $273 $70,315 
Net income8,146 8,146 12 8,159 
Other comprehensive income/(loss), net of tax
(891)(891)(3)(894)
Cash dividends declared, per share: $0.39
Common stock(2,192)(2,192)(2,192)
Preferred stock—  
Noncontrolling interests